The genomic profile of <i>HER2</i>‐amplified breast cancers: the influence of ER status
Caterina Marchiò(Candiolo Cancer Institute), JS Reis‐Filho(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Narinder Tamber(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Anna Sapino(Candiolo Cancer Institute), José Palacios(Universidad de Alcalá), Kerry Fenwick(Institute of Cancer Research), SM Rodriguez‐Pinilla(Spanish National Cancer Research Centre), K-K. Shiu(Institute of Cancer Research), D. Hungermann(University Hospital Münster), MBK Lambros(Institute of Cancer Research), Horst Buerger
Cited by 75
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k